MRK vs SBUX: Which Is the Better Buy?

Side-by-side comparison of Merck & Co., Inc. and Starbucks Corporation โ€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-09-18.
Merck & Co., Inc. ยท Healthcare
$147.17
-4.1% upside to fair value
Med Conviction Grade C
VS
Starbucks Corporation ยท Consumer Cyclical
$96.67
+12.3% upside to fair value
Med Conviction Grade C
QuantHub Verdict
SBUX has more upside to fair value (+12.3%). These are model outputs โ€” not personalized investment advice. See all research โ†’
Valuation & Fundamentals
Metric MRK SBUX
Current Price $147.17 $96.67
Fair Value Estimate $141.07 $108.52
Upside to Fair Value -4.1% +12.3%
Market Cap $363.5B $110.2B
Forward P/E โ€” โ€”
EV / EBITDA 29.6x 22.0x
Price / Sales 5.5x 2.9x
Price / FCF 22.6x 30.4x
Revenue Growth YoY +5.1% -1.4%
Gross Margin 75.4% 31.7%
Operating Margin 16.7% 9.4%
Return on Equity 6.6% -24.3%
Dividend Yield 2.31% 2.57%
FCF Yield 4.42% 3.29%
Analyst Consensus Buy Buy
Investment Thesis
MRK โ€” Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with two core divisions, Pharmaceuticals and Animal Health, spanning oncology, vaccines, acute hospital care, immunology, neuroscience, virology, cardiovascular and diabetes, and it employs roughly 74,000 people under CEO Robert Davis. The business quality is medium: TTM gross margin of 75.4% and TTM operating margin of 16.7% reflect a genuinely higโ€ฆ
SBUX โ€” Starbucks Corporation
Starbucks is the world's largest specialty coffee retailer, operating company-owned and licensed coffeehouses across North America, International, and Channel Development segments, with a brand that has historically supported premium pricing and global scale. The business quality is currently strained: revenue declined 1.4% year over year in the most recent quarter, TTM operating margin is 9.4%, โ€ฆ
Accumulation Zones
Metric MRK SBUX
Zone Low $105.80 $81.39
Zone High $119.91 $92.24
In Buy Zone? No No
โ† MRK Research    SBUX Research โ†’    All Research